Our Bureau, Chennai Friday, July 4, 2025, 12:45 Hrs [IST] Pharmac South 2025, the 10th edition of South India's high-power ...

CytoDyn announces encouraging clinical findings among patients with advanced metastatic colorectal cancer previously treated with leronlimab: Vancouver, Washington Friday, July 4, ...

Lupin introduces ipratropium bromide nasal solution, 0.03% & 0.06% in US markets: Our Bureau, Mumbai Friday, July 4, 2025, 17:30 Hrs [IST] Global pharma major Lupin Limited (Lupin ...

Nuravax, Institute for Molecular Medicine to present phase 1 results & phase 2 design of Alzheimer’s vaccine AV-1959R at CTAD 2025: Irvine, California Friday, July 4, 2025, 17:0 ...

Jaslok Hospital performs first-of-its-kind lutetium therapy saving terminal prostate cancer patient: Our Bureau, Mumbai Friday, July 4, 2025, 17:15 Hrs [IST] In a first-of-its-kin ...

Inmagene enrolls first patient in ADAPTIVE phase 2b clinical trial of IMG-007: San Diego Friday, July 4, 2025, 15:00 Hrs [IST] Inmagene Biopharmaceuticals (Inmagene), a clinical-s ...

PHARMASEAL announces Technical Integration Partnership with Viedoc: Nottingham, UK Friday, July 4, 2025, 16:00 Hrs [IST] PHARMASEAL, provider of the Engility Trial Management Plat ...

NS Pharma announces alliance with Boston Children’s Hospital to develop new therapies for rare diseases: Paramus, New Jersey Friday, July 4, 2025, 12:00 Hrs [IST] Paramus-headqu ...

Jacobio Pharma submits phase I/II IND application for its BET inhibitor, JAB-8263 to treat autoimmune diseases to CDE in China: Beijing, Shanghai Friday, July 4, 2025, 13:00 Hrs [ ...

Sunshine Biopharma’s Canadian subsidiary, Nora Pharma launches biosimilar drug, Niopeg: Fort Lauderdale, Florida Friday, July 4, 2025, 14:00 Hrs [IST] Sunshine Biopharma Inc., a ...

Zyla Health expands in Southeast Asia, empowering patients with personalised digital therapeutics: Our Bureau, Mumbai Friday, July 4, 2025, 11:30 Hrs [IST] Zyla Health, India’s ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...